• News

New Data Highlights Etrasimod’s Potential for Atopic Dermatitis

  • HCPLive
  • New York, NY
  • (April 23, 2021)

Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, offers promise as a new therapeutic option for atopic dermatitis, according to a late-breaking study presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021.

Learn more